Status Epilepticus Management — Status epilepticus medication sequence (overview) - Pharmacology

SECTION 1

Historical Context & Motivation

Status epilepticus (SE) represents one of the most dangerous neurological emergencies encountered in clinical medicine, defined as continuous seizure activity lasting five minutes or longer, or two or more discrete seizures without full recovery of consciousness between them. Historically, the management of prolonged seizures was haphazard and often lethal, with mortality rates exceeding 50% before the introduction of systematic pharmacologic protocols. The evolution of our treatment approach reflects advances in understanding GABA_A receptor pharmacology, seizure pathophysiology, and the critical importance of time-dependent receptor trafficking that makes early aggressive treatment essential. The recognition that benzodiazepine efficacy declines rapidly with prolonged seizure duration fundamentally reshaped emergency treatment algorithms and led to the structured, stepwise medication sequence used today.

1960s • Introduction of IV Diazepam

Intravenous diazepam becomes the first widely adopted pharmacologic intervention for acute seizure termination, replacing barbiturate-only regimens. Its rapid onset via GABA_A receptor potentiation demonstrates the viability of benzodiazepine-based approaches.

1983 • VA Cooperative Study

Landmark Veterans Affairs cooperative study begins comparing lorazepam, diazepam, phenytoin, and phenobarbital in generalized convulsive status epilepticus, ultimately establishing lorazepam as a first-line agent due to its longer duration of action and superior seizure control.

1993 • Epilepsy Foundation Guidelines

The Epilepsy Foundation of America publishes the first formal treatment guidelines proposing a time-based, staged approach to SE management, formalizing the concept of sequential medication escalation.

2012 • RAMPART Trial

The Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) demonstrates that intramuscular midazolam is non-inferior to IV lorazepam for prehospital seizure termination, expanding first-line options when IV access is unavailable.

2020 • ESETT Trial Published

The Established Status Epilepticus Treatment Trial (ESETT) shows that fosphenytoin, levetiracetam, and valproate are equally effective as second-line agents for benzodiazepine-refractory SE, reshaping the second-line treatment paradigm.

The central question that these decades of research address is deceptively simple: In what order and at what time points should medications be administered to maximize seizure termination while minimizing morbidity and mortality? The answer, as we will see, involves a carefully choreographed escalation from benzodiazepines through antiseizure medications to anesthetic agents, each stage guided by the evolving neurochemistry of the seizing brain.

SECTION 2

Core Principles of SE Management

Effective management of status epilepticus rests on several interconnected pharmacologic and physiologic principles that explain why a rigid, time-driven treatment protocol is necessary. Understanding these foundational concepts transforms what might appear to be a simple drug checklist into a rational, mechanism-based therapeutic strategy.

Time Is Brain

Neuronal injury begins within minutes of continuous seizure activity. Excitotoxicity mediated by glutamate, oxidative stress, and metabolic failure cause irreversible neuronal death. Earlier treatment yields significantly higher seizure termination rates—benzodiazepines are effective in approximately 80% of cases when given within 5 minutes, but only 40% after 30 minutes.

GABA Receptor Internalization

As seizures persist, GABA_A receptors undergo clathrin-mediated endocytosis from the synaptic membrane. This receptor trafficking explains why benzodiazepine efficacy diminishes over time and why second- and third-line agents with non-GABAergic mechanisms become necessary.

NMDA Receptor Upregulation

Simultaneously, NMDA-type glutamate receptors are trafficked to the postsynaptic membrane, increasing excitatory signaling. This dual process—loss of inhibition and gain of excitation—creates a self-sustaining seizure state that becomes progressively pharmacoresistant.

Staged Escalation

Treatment is organized into three distinct stages: initial therapy (benzodiazepines), second-line or urgent control therapy (antiseizure medications such as fosphenytoin, levetiracetam, or valproate), and third-line or refractory therapy (continuous IV anesthetics). Each stage is triggered by failure of the preceding stage.

ABCs and Supportive Care

Pharmacologic treatment does not occur in isolation. Concurrent management of airway, breathing, circulation, glucose, electrolytes, and temperature is essential. Respiratory depression from benzodiazepines and anesthetics requires continuous monitoring and readiness for intubation.

✦

KEY TAKEAWAY

Think of the seizing brain like a fire in a building. In the first few minutes (Stage 1), a fire extinguisher (benzodiazepine) can usually put it out because the fire is small and the extinguisher is effective. But the longer the fire burns, the more it weakens the building's fire-suppression sprinkler system (GABA_A receptor internalization) while simultaneously feeding the flames with more fuel (NMDA receptor upregulation). After several minutes, you need the fire department's hoses (second-line agents), and if the blaze is still raging, you call in specialized teams with heavy equipment (anesthetics and ICU management). Every minute of delay allows the fire to grow and become harder to extinguish.

SECTION 3

The Medication Sequence — Visual Overview

The following diagram illustrates the time-based, staged approach to status epilepticus management. Each stage is defined by a time window from seizure onset, the class of medication administered, and the decision point that triggers escalation to the next stage. Note how the treatment protocol is organized around absolute time benchmarks rather than arbitrary clinical assessments, reflecting the evidence that every minute of delay reduces the probability of seizure termination.

The three primary stages of SE management are organized by time from seizure onset. Stage 1 (green) deploys benzodiazepines within the first 5 minutes. Stage 2 (amber) introduces an antiseizure medication by 20 minutes if seizures persist. Stage 3 (red) escalates to continuous IV anesthetics by 40 minutes. Supportive care measures (center band) run concurrently throughout.

As illustrated above, the treatment algorithm is driven by time-based decision nodes rather than subjective clinical judgment. The diagram highlights a critical clinical reality: if the initial benzodiazepine dose does not terminate seizure activity within five minutes, a second dose may be given, but the clinician should simultaneously begin preparing the second-line agent so there is no delay in escalation. The parallel preparation principle is a hallmark of modern SE management—each stage should be anticipated and made ready before it is needed. The dashed border around super-refractory SE (bottom) indicates that this category, defined as seizures persisting or recurring 24 hours or more after the initiation of anesthetic therapy, remains the most therapeutically challenging and carries the highest mortality.

SECTION 4

Pharmacologic Mechanisms at Each Stage

Each stage of the SE treatment algorithm targets distinct neurochemical pathways, and the rationale for escalation is grounded in the evolving receptor landscape of the seizing brain. Understanding these mechanisms explains not only why specific drugs are chosen but also why their order matters.

Stage 1: Benzodiazepines — Enhancing GABAergic Inhibition

Benzodiazepines act as positive allosteric modulators at the GABA_A receptor, binding to the interface between the α and γ subunits to increase the frequency of chloride channel opening when GABA binds. This enhances inhibitory postsynaptic currents without directly activating the receptor in the absence of GABA—a pharmacologic distinction that limits toxicity compared to barbiturates. Lorazepam is preferred over diazepam for IV administration because its lower lipophilicity results in less rapid redistribution from the brain, providing a longer effective duration of action (12–24 hours versus 15–20 minutes for diazepam). When IV access is unavailable, intramuscular midazolam is the agent of choice because of its rapid and reliable absorption from muscle tissue, as demonstrated in the RAMPART trial.

Stage 2: Antiseizure Medications — Sodium Channel Blockade and Beyond

When benzodiazepines fail—either because of GABA_A receptor internalization or inadequate dosing—the protocol calls for second-line agents that operate through different mechanisms. Fosphenytoin (the water-soluble prodrug of phenytoin) blocks voltage-gated sodium channels in a use-dependent manner, preferentially suppressing the rapid, repetitive firing characteristic of seizures while sparing normal neuronal activity. Levetiracetam binds to the synaptic vesicle glycoprotein SV2A, modulating neurotransmitter release and reducing excitatory synaptic transmission. Valproate has a broad mechanism of action including sodium channel blockade, enhanced GABAergic transmission, and NMDA receptor antagonism. The ESETT trial (2019) demonstrated that all three agents are equally effective at about 45–50% seizure termination rate, so the choice among them is often guided by patient-specific factors such as hepatic function, pregnancy status, and concomitant medications.

Stage 3: Continuous IV Anesthetics — Global CNS Suppression

If seizures continue despite two medication stages, the patient has entered refractory status epilepticus, which requires pharmacologic coma induction. Midazolam, propofol, and pentobarbital are the primary agents. Midazolam infusion acts via the same GABA_A mechanism as bolus benzodiazepines but at higher sustained concentrations. Propofol enhances GABA_A receptor activity and blocks sodium channels and NMDA receptors, producing broad-spectrum CNS suppression. Pentobarbital, as a barbiturate, directly activates GABA_A receptors by increasing chloride channel open duration, providing the most profound level of suppression. All three agents require endotracheal intubation, mechanical ventilation, vasopressor support, and continuous EEG monitoring to titrate to a burst-suppression pattern.

This diagram illustrates the dynamic receptor changes during status epilepticus. Green circles represent GABA_A receptors (inhibitory), and red circles represent NMDA receptors (excitatory). As SE progresses from normal to early SE to prolonged SE, GABA_A receptors are internalized (removed from the membrane) while NMDA receptors are trafficked to the surface, explaining the declining efficacy of benzodiazepines and the need for agents with different mechanisms.

SECTION 5

Detailed Drug Selection by Stage

Selecting the appropriate agent at each stage requires knowledge of pharmacokinetics, contraindications, and adverse effect profiles. The following table provides a comprehensive comparison of the major agents used across all three stages, organized by their clinical role in the SE treatment sequence.

Drug	Stage	Mechanism	Dose	Key Considerations
Lorazepam (IV)	1st line	GABA_A positive allosteric modulator	0.1 mg/kg IV (max 4 mg/dose); may repeat ×1	Longer CNS duration than diazepam; respiratory depression; requires refrigeration
Midazolam (IM)	1st line (no IV)	GABA_A positive allosteric modulator	10 mg IM (>40 kg); 5 mg IM (13–40 kg)	Rapid IM absorption; autoinjector available; RAMPART trial validated
Diazepam (rectal)	1st line (home/prehospital)	GABA_A positive allosteric modulator	0.2 mg/kg PR (max 20 mg)	Rapid redistribution limits duration; used in seizure rescue plans
Fosphenytoin	2nd line	Voltage-gated Na⁺ channel blockade (use-dependent)	20 mg PE/kg IV at 150 mg PE/min	Arrhythmia risk (cardiac monitoring); avoid in known cardiac conduction disease; not sedating
Levetiracetam	2nd line	SV2A binding; modulates neurotransmitter release	60 mg/kg IV (max 4500 mg) over 15 min	Favorable safety profile; no drug interactions; behavioral side effects
Valproate	2nd line	Na⁺ channel blockade, ↑ GABA, NMDA antagonism	40 mg/kg IV (max 3000 mg) over 10 min	Contraindicated in pregnancy, hepatic disease, mitochondrial disorders; broad spectrum
Propofol infusion	3rd line	GABA_A agonism, Na⁺/NMDA blockade	1–2 mg/kg bolus, then 20–60 µg/kg/min	Propofol infusion syndrome risk (monitor triglycerides, lactate, CK); rapid on/off
Pentobarbital infusion	3rd line	Direct GABA_A agonist (↑ Cl⁻ channel open duration)	5 mg/kg bolus, then 1–5 mg/kg/hr	Most potent suppression; profound hypotension; prolonged recovery; immunosuppression

Comprehensive medication reference for all stages of SE management

⚠

Clinical Pearl

A common clinical error is underdosing benzodiazepines during Stage 1. Weight-based dosing (0.1 mg/kg for lorazepam) means an 80 kg patient should receive 8 mg total (two 4 mg doses). Giving only a single 2 mg dose—as frequently occurs in practice—reduces efficacy and wastes the window of maximal GABA_A receptor availability. Subtherapeutic dosing is not 'being cautious'—it is delaying effective treatment.

SECTION 6

Worked Clinical Scenario

The following scenario demonstrates the application of the SE medication sequence to a realistic clinical case, illustrating the decision points and dosing calculations at each stage.

Management of Generalized Convulsive Status Epilepticus

1
Step 1 — Assess and Stabilize (T = 0 min)

A 72 kg adult male is brought to the emergency department by paramedics with ongoing generalized tonic-clonic seizures witnessed for 7 minutes. On arrival: GCS 3, SpO₂ 88% on room air, HR 130, BP 180/100. Immediate actions: position patient on side, apply supplemental oxygen via non-rebreather mask, place two large-bore IVs, obtain point-of-care glucose (result: 110 mg/dL, normal), and draw blood for CBC, BMP, hepatic panel, antiseizure drug levels, and toxicology screen.

ABCs secured. IV access established. Glucose normal — no need for dextrose or thiamine.
2
Step 2 — Stage 1: Benzodiazepine Administration (T = 2 min)

With IV access confirmed, administer lorazepam IV. Calculate the dose: 0.1 mg/kg × 72 kg = 7.2 mg, given as an initial dose of 4 mg IV push (maximum single dose). Observe for seizure cessation over 3–5 minutes while monitoring respiratory status. At T = 7 min, seizures persist. Administer a second dose of lorazepam 4 mg IV (cumulative total: 8 mg, within the recommended 0.1 mg/kg total). Ensure bag-valve-mask and intubation equipment are at bedside in case of respiratory depression.

Lorazepam 4 mg IV × 2 doses given. Seizures continue at T = 12 min → Benzodiazepine failure → Proceed to Stage 2.
3
Step 3 — Stage 2: Second-Line Antiseizure Medication (T = 12 min)

Seizures continue despite two adequate doses of lorazepam. The team has been preparing the second-line agent in parallel. Given no known cardiac history, no liver disease, and no pregnancy, any of the three ESETT-equivalent agents may be chosen. The team selects fosphenytoin. Calculate the dose: 20 mg PE/kg × 72 kg = 1440 mg PE, infused IV at a maximum rate of 150 mg PE/min. This requires approximately 9.6 minutes to infuse. Continuous cardiac monitoring is initiated for the infusion due to the risk of QT prolongation and hypotension. Observe for 5 minutes after the infusion completes.

Fosphenytoin 1440 mg PE infused over ~10 min. Seizures continue at T = 30 min → Stage 2 failure → Proceed to Stage 3.
4
Step 4 — Stage 3: Refractory SE — Continuous Anesthetic (T = 30 min)

The patient now meets criteria for refractory status epilepticus. The decision is made to intubate and initiate a continuous midazolam infusion. Anesthesiology is called for airway management. After rapid-sequence intubation, midazolam is administered as a loading dose of 0.2 mg/kg = 14.4 mg IV bolus, followed by a continuous infusion starting at 0.1 mg/kg/hr = 7.2 mg/hr. Continuous EEG (cEEG) monitoring is connected. The infusion is titrated upward in increments of 0.05 mg/kg/hr every 15 minutes until seizure suppression or a burst-suppression pattern is achieved on cEEG. The patient is admitted to the neurological ICU.

Midazolam infusion initiated. cEEG shows burst-suppression at 0.2 mg/kg/hr. Seizure activity controlled at T = 50 min.
5
Step 5 — Post-Stabilization Management

Once seizure activity is controlled, the anesthetic infusion is maintained for 24–48 hours while a maintenance antiseizure medication is loaded (e.g., levetiracetam 1500 mg IV q12h). The infusion is then slowly weaned under cEEG monitoring. If seizures recur during the wean, the diagnosis becomes super-refractory SE, and additional interventions such as ketamine, immunotherapy, or alternative anesthetics may be considered. A thorough etiology workup—including brain MRI, lumbar puncture, and autoimmune/infectious panels—is completed during the ICU stay.

Patient successfully weaned from midazolam at 48 hours without seizure recurrence. Transitioned to oral levetiracetam with neurology follow-up.

SECTION 7

Strengths and Limitations of Each Agent Class

No single agent is ideal for all clinical scenarios, and understanding the comparative advantages and disadvantages of each drug class guides appropriate selection. The following table presents a side-by-side comparison of the three major agent classes organized by their therapeutic stage.

Feature	Benzodiazepines (Stage 1)	ASMs (Stage 2)	Anesthetics (Stage 3)
Onset of action	1–3 min (IV); 3–5 min (IM)	10–30 min (depending on infusion rate)	Immediate (IV bolus)
Efficacy (initial)	~65–80% if given early	~45–50% (ESETT data)	>90% (induces pharmacologic coma)
Key advantage	Rapid onset; multiple routes (IV, IM, PR, IN, buccal)	Sustained seizure control; varied mechanisms	Most reliable seizure termination; broad receptor activity
Key limitation	Efficacy declines with time; respiratory depression	Slower onset; drug-specific contraindications	Requires ICU/intubation; hemodynamic instability; prolonged recovery
Sedation	Moderate	Minimal (fosphenytoin, LEV) to moderate (VPA)	Profound (pharmacologic coma)
Airway management	Monitor closely; intubation may be needed	Generally not required for drug alone	Mandatory intubation and mechanical ventilation
Monitoring	SpO₂, respiratory rate, BP	ECG (fosphenytoin); hepatic function (VPA)	Continuous EEG, arterial line, central access

Comparison of SE treatment agent classes across key clinical parameters

✦

KEY TAKEAWAY

Think of the SE medication sequence like the graduated response protocols used by emergency management agencies during a natural disaster. A local fire department (benzodiazepines) responds first because they arrive quickly and handle most situations. If they cannot contain the event, regional resources (second-line ASMs) are deployed—they take longer to mobilize but bring additional capabilities. If the disaster still overwhelms, federal resources and the National Guard (anesthetics, ICU-level care) are activated—they bring maximum force but require enormous logistical support. Each escalation level involves more resources, more risk, and more infrastructure, which is why you always start with the fastest, simplest intervention and escalate only as needed.

SECTION 8

Connection to Advanced Concepts

The staged approach to SE management described in this lesson represents the foundation upon which more advanced topics in epilepsy pharmacology are built. Understanding where this basic framework intersects with cutting-edge research and complex clinical scenarios prepares students for the depth of knowledge required in advanced pharmacology and neurocritical care rotations.

Basic SE Protocol Concept	Advanced Extension
Benzodiazepines as first-line agents	GABA receptor subunit pharmacology—why α1-selective BZDs might offer advantages; neurosteroid development (allopregnanolone/brexanolone) as novel GABA modulators with activity at internalized receptors
GABA receptor internalization concept	Receptor trafficking kinetics and molecular biology of clathrin-mediated endocytosis; potential therapeutic targets to prevent receptor loss (e.g., calcineurin inhibitors)
Equivalent efficacy of ESETT agents	Pharmacogenomics—CYP2C9/CYP2C19 polymorphisms affecting phenytoin metabolism; SV2A receptor variant effects on levetiracetam response; precision medicine approaches to SE
Refractory SE requiring anesthetics	Ketamine as a rational NMDA antagonist for SE that has upregulated excitatory receptors; immunotherapy for autoimmune-mediated refractory SE (anti-NMDAR encephalitis)
Super-refractory SE (>24 hr)	Ketogenic diet for seizure control via metabolic pathways; therapeutic hypothermia; electroconvulsive therapy; vagus nerve stimulation; cannabidiol and novel investigational agents

From foundational SE management to advanced pharmacologic and translational concepts

One of the most exciting areas of current research is the development of neurosteroids such as allopregnanolone (brexanolone), which modulate GABA_A receptors at both synaptic and extrasynaptic sites and may retain efficacy even after synaptic receptor internalization. This represents a potential paradigm shift: rather than escalating to agents with entirely different mechanisms, future protocols might employ drugs that continue to leverage GABAergic inhibition through alternative receptor populations. Additionally, the growing recognition of autoimmune etiologies of SE—particularly anti-NMDA receptor encephalitis—has introduced immunotherapy (IVIG, plasmapheresis, rituximab) as a crucial intervention that operates on a fundamentally different therapeutic axis than any antiseizure medication.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why benzodiazepine efficacy declines as status epilepticus progresses. What molecular mechanism accounts for this phenomenon, and how does it influence the design of the staged treatment protocol?

Show answer

As status epilepticus continues, GABA_A receptors undergo clathrin-mediated endocytosis (internalization), removing them from the postsynaptic membrane. Since benzodiazepines are positive allosteric modulators that require functional GABA_A receptors to exert their effect, the progressive loss of these receptors directly diminishes benzodiazepine efficacy. Simultaneously, excitatory NMDA receptors are trafficked to the synaptic surface, further tipping the balance toward excitation. This dual process explains why the treatment protocol mandates time-based escalation to second-line agents with non-GABAergic mechanisms (such as sodium channel blockade by fosphenytoin or SV2A binding by levetiracetam) rather than simply giving more benzodiazepines.

Question 2: BASIC CALCULATION

A 55 kg woman presents with generalized convulsive status epilepticus. Calculate the appropriate IV lorazepam dose for the first bolus and the maximum total benzodiazepine dose she can receive during Stage 1. If she fails benzodiazepines and levetiracetam is chosen as the second-line agent, what dose should be administered?

Show answer

For lorazepam, the weight-based dose is 0.1 mg/kg total, which equals 0.1 × 55 = 5.5 mg total. Since the maximum single dose is 4 mg, the first bolus is 4 mg IV push. If seizures persist after 5 minutes, a second dose of 1.5 mg (to complete the total of 5.5 mg) or a full second 4 mg dose may be given depending on institutional protocol—many guidelines permit up to 4 mg × 2 = 8 mg in practice. For levetiracetam as a second-line agent, the dose is 60 mg/kg IV = 60 × 55 = 3300 mg, which should be infused over approximately 15 minutes. This dose is within the maximum recommended dose of 4500 mg.

Question 3: INTERMEDIATE

A 68-year-old patient with a history of hepatic cirrhosis (Child-Pugh Class C) and known prolonged QT interval on baseline ECG presents with status epilepticus that is refractory to two doses of lorazepam. Which second-line agent would you select, and why? Explain the reasoning for excluding each of the other two ESETT agents.

Show answer

Levetiracetam is the best choice in this clinical scenario. Valproate must be excluded because it is hepatotoxic and is contraindicated in significant liver disease—Child-Pugh Class C cirrhosis represents severe hepatic impairment where valproate could precipitate acute liver failure and would also have unpredictable pharmacokinetics due to reduced protein binding and impaired metabolism. Fosphenytoin must be excluded because it carries a risk of cardiac arrhythmias, including QT prolongation and bradycardia, and is specifically dangerous in a patient with a known prolonged QT interval—infusion could trigger torsades de pointes. Levetiracetam has minimal hepatic metabolism (primarily renal elimination via enzymatic hydrolysis), no significant cardiac effects, and essentially no drug interactions, making it the safest option for this patient. The dose of 60 mg/kg IV should be adjusted if there is concurrent renal impairment, which should be assessed.

Question 4: APPLIED

You are a paramedic responding to a school where a 14-year-old boy (estimated weight 50 kg) is actively seizing. Witnesses report seizure onset approximately 8 minutes ago. You do not have IV access. Describe your initial pharmacologic management, including the specific drug, route, and dose. Then explain what you would communicate to the receiving emergency department to facilitate seamless transition to Stage 2 if needed.

Show answer

Without IV access and with seizures lasting >5 minutes, the first-line treatment is intramuscular midazolam. For a patient weighing 50 kg (which is above 40 kg), the dose is 10 mg IM, administered into the lateral thigh using an autoinjector or standard IM injection technique. This dosing was validated by the RAMPART trial, which demonstrated non-inferiority to IV lorazepam in the prehospital setting. Simultaneously, basic stabilization should be performed: position the patient on his side, protect the airway, provide oxygen, and obtain a blood glucose level. When communicating with the receiving ED, the paramedic should relay: (1) the time of seizure onset and total duration; (2) the drug, dose, route, and time of midazolam administration; (3) whether any seizure cessation was observed; and (4) the patient's weight. This allows the ED team to prepare a second-line agent immediately and avoids the common error of re-dosing benzodiazepines rather than escalating to Stage 2 when the patient arrives still seizing.

Question 5: CRITICAL THINKING

A patient has been on a continuous midazolam infusion for refractory SE for 30 hours. Continuous EEG shows burst-suppression. The ICU team attempts to wean the infusion, but seizures recur within 2 hours of dose reduction. This patient now meets criteria for super-refractory SE. Analyze why simply increasing the midazolam infusion rate is unlikely to be sufficient as a long-term strategy. Discuss at least two mechanistically distinct therapeutic approaches that could be considered, and explain the pharmacologic rationale for each.

Show answer

Simply increasing midazolam is problematic for several reasons: tachyphylaxis (tolerance) develops rapidly through continued GABA_A receptor downregulation; higher doses produce worsening hemodynamic instability, immunosuppression, and ileus; and the fundamental receptor landscape has shifted so dramatically that GABAergic agents alone cannot restore the excitatory-inhibitory balance. Two mechanistically distinct approaches include: (1) Ketamine infusion—as an NMDA receptor antagonist, ketamine directly addresses the upregulated excitatory glutamate receptors that have been trafficked to the synapse during prolonged SE. Since the pathophysiology involves both loss of inhibition and gain of excitation, blocking the excitatory arm provides a complementary strategy to GABAergic agents. Ketamine also has neuroprotective properties and is less likely to cause hemodynamic compromise than barbiturates. (2) Immunotherapy (IVIG, plasmapheresis, or rituximab)—this approach is based on the recognition that a subset of super-refractory SE cases are driven by autoimmune etiologies such as anti-NMDA receptor encephalitis. In these cases, the seizures are perpetuated by autoantibodies against neuronal surface antigens, and no antiseizure medication will be effective unless the autoimmune process is treated. This represents a fundamentally different therapeutic axis—targeting the etiology rather than the symptom. Additional approaches could include the ketogenic diet (which alters brain metabolism to favor ketone body utilization and may have direct antiseizure effects) or therapeutic hypothermia (which reduces cerebral metabolic rate and excitotoxicity).

SUMMARY

Status Epilepticus Medication Sequence — Summary

Summary

Status epilepticus is a life-threatening neurological emergency defined as continuous seizure activity lasting five minutes or longer. Management follows a strict, time-based, three-stage protocol. Stage 1 (0–5 minutes) employs benzodiazepines — IV lorazepam (0.1 mg/kg, max 4 mg/dose) or IM midazolam (10 mg) — which act as positive allosteric modulators at GABA-A receptors. Stage 2 (by 20 minutes) introduces one of three equipotent second-line agents — fosphenytoin, levetiracetam, or valproate — each with a distinct mechanism of action (sodium channel blockade, SV2A binding, or multi-target activity, respectively). Stage 3 (by 40 minutes) escalates to continuous IV anesthetics (midazolam, propofol, or pentobarbital infusions), which require intubation, ICU admission, and continuous EEG monitoring.

The rationale for this escalating approach is rooted in the neurobiology of prolonged seizures: as SE continues, GABA-A receptors undergo internalization while NMDA receptors are upregulated, creating a self-sustaining seizure state that becomes progressively pharmacoresistant. This explains why early, adequate-dose benzodiazepine treatment is the single most important modifiable factor in SE outcomes. Throughout all stages, concurrent supportive care — airway management, hemodynamic monitoring, glucose assessment, and etiologic workup — must proceed in parallel. Cases refractory to all three stages (super-refractory SE) represent the frontier of epilepsy pharmacology, with emerging approaches including ketamine, neurosteroids, immunotherapy, and the ketogenic diet.